Study details
Enrolling now
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Upstream Bio Inc.
NCT IDNCT06981078ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
666
Study length
about 3.1 years
Ages
40–85
Locations
32 sites in CA, CO, FL +9
About this study
This trial is testing a treatment called verekitug (UPB-101) in people with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). The goal is to see if this treatment helps improve symptoms and is safe for them.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Verekitug
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low6%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Change in pre-bronchodilator forced expiratory capacity in 1 second (FEV1), Incidence of treatment-emergent adverse events and serious adverse events
Body systems
Respiratory